Vendela Ekmark - Onkologi i Sverige

Imfinzi plus kemoterapi minskade risken för död med 20% i 1a linjen vid gallvägscancer

Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer

TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting.
Combination did not increase discontinuations due to adverse events vs. chemotherapy alone.

Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).

These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Läs hela pressmeddelandet här

Imfinzi plus tremelimumab visade oöverträffad överlevnad i 1a linjen vid icke resekterbar levercancer

Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years

A single priming dose of tremelimumab plus Imfinzi every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial.
Combination also showed no increase in severe liver toxicity and fewer discontinuations due to treatment-related adverse events vs. sorafenib.

Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment.

This novel dose and schedule of Imfinzi and tremelimumab, an anti-CTLA4 antibody, is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab). Results from the trial will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Läs hela pressmeddelandet här

NORDIC HEMATOLOGY DEBATE

For the 6th year in a row we hereby invite you to NORDIC HEMATOLOGY DEBATE with international experts. 2022 years Nordic Hematology Debate will cover advances in treatment of Chronic Lymphocytic Leukemia, Multiple Myeloma, Mantle Cell Lymphoma, and Immunotherapy.

During the meeting you will be updated on the current treatment practice and the latest scientifi c and clinical advances within each area.
This meeting is intended for physicians, both specialists and those during education in hematology and oncology with interest in above areas.

For more inf0rmation and registration

Issues in the management of relapsed and refractory diffuse large B-cell lymphoma in 2022 with focus on new therapies

Incyte Nordics has the pleasure to invite you to a virtual meeting where Georg Hess, MD and professor at the hematology department at the Johannes Gutenburg University in Mainz, Germany will present the latest scientific data in the treatment of patients with R/R DLBCL.

Wednesday 23rd of March

15.00 – 16.30 CET

For more information and registration click here

Värdet av cirkulerande tumörDNA (ctDNA)

Tid: 12.10–12.50

Värdet av cirkulerande tumörDNA (ctDNA) för patienter med bröstcancer
En föreläsning av Barbro Linderholm, Bröstonkolog Sahlgrenska

ctDNA kan kallas en ”liquid biopsy” som kan användas för att kvantifiera nivån av ctDNA och för att karakterisera sjukdomen med genexpressionsprofiler. Man kan alltså monitorera sjukdomen och till exempel identifiera recidiv tidigare än vad vi gör i klinisk rutin. Om detta gagnar patienterna är dock inte klarlagt.
Vid metastatisk bröstcancer där biologin ändras kontinuerligt finns förhoppningar att dessa förändringar ska kunna följas genom analys av ctDNA från plasma. Ett nyare användningsområde är att analysera ctDNA från liquor och kunna få mer detaljerad biologisk kartläggning av CNS metastaser.

Klicka här för mer information och anmälan